Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models

Clinical Cancer Research

Volumn 20, Issue 6, 2014, Pages 1555-1565

  Candolfi, Marianela ^a,b   Yagiz, Kader ^a,b   Wibowo, Mia ^a,b   Ahlzadeh, Gabrielle E ^a,b   Puntel, Mariana ^a,b   Ghiasi, Homayon ^a   Kamran, Neha ^a,b   Paran, Christopher ^a,b   Lowenstein, Pedro R ^a,b   Castro, Maria G ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLT3 LIGAND; GANCICLOVIR; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; GLIOBLASTOMA; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR VOLUME; WILD TYPE; ADENOVIRIDAE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN TUMOR; C57BL MOUSE; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; PATHOLOGY; PROCEDURES;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; THYMIDINE KINASE;

EID: 84896505764     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2140     Document Type: Article

References (39)

1. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 2003;15:197-203.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life 2009;2:386-93.
4. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
5. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. ClinCancer Res 2009;15:4401-14.
6. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009;6:e10.
7. Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009;15: 6113-27.
8. Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, et al. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 2012;14:757-70.
9. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007;85:133-48.
10. Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 2009;95:191-7.
11. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, et al. Combined immunostimulationandconditional cytotoxicgenetherapy provide longterm survival in a large glioma model. Cancer Res 2005;65:7194-204.
12. Southgate T, Kroeger KM, Liu C, Lowenstein PR, Castro MG. Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci 2008; Chapter 4:Unit 4.23.
13. Allen SJ, Mott KR, Chentoufi AA, BenMohamed L, Wechsler SL, Ballantyne CM, et al. CD11c controls herpes simplex virus 1 responses to limit virus replication during primary infection. J Virol 2011;85:9945-55.
14. Wu H, Rodgers JR, Perrard XY, Perrard JL, Prince JE, Abe Y, et al. Deficiency of CD11b or CD11d results in reduced staphylococcal enterotoxin-induced T cell response and T cell phenotypic changes. J Immunol 2004;173:297-306.
15. Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 2011;13:947-60.
16. Watanabe R, Nakasu Y, Tashiro H, Mitsuya K, Ito I, Nakasu S, et al. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. Brain Tumor Pathol 2011;28:127-35.
17. Seligman A, Shear M. Studies in carcinogenesis. VIII. experimental production of brain tumors in mice with methylcholanthrene. American J Cancer 1939;37:364-95.
18. Sugiura KTumor Transplantation. In:Gay W, Editor. Methods of Animal Experimentation. New York: Academic Press, Inc; 1969. p. 171-222.
19. Lee JH, Jung TY, Jung S, Kim IY, Jang WY, Moon KS, et al. Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. J Clin Neurosci 2013;20:503-8.
20. Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hídvegi EJ, Hamada H, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006;97:546-53.
21. Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97:377-81.
22. Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011; 102:311-6.
23. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greaterchemotherapy-inducedlymphopenia enhances tumorspecific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13:324-33.
24. Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, et al. Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS ONE 2013;8:e59082.
25. Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol 2012;2012:831090.
26. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 2010;17:143-53.
27. Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 2011; 104:83-92.
28. Fadul CE, Fisher JL, Gui J, Hampton TH,C^ote AL, ErnstoffMS. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 2011;13:393-400.
29. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009;58:1627-34.
30. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011;118:3003-12.
31. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
32. Tentori L, Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 2009;16:245-57.
33. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-26.
34. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
35. Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 2011;29:3611-9.
36. Rainov NG, Fels C, Droege JW, Schäfer C, Kramm CM, Chou TC. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther 2001;8:662-8.
37. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 2010;99:261-72.
38. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 2008;15: 114-21.
39. Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2012;77:736-44.